Synovus Financial Corp Acquires 2,684 Shares of Novo Nordisk A/S (NYSE:NVO)

Synovus Financial Corp boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,697 shares of the company’s stock after purchasing an additional 2,684 shares during the period. Synovus Financial Corp’s holdings in Novo Nordisk A/S were worth $6,513,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of NVO. International Assets Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC boosted its stake in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $98,765,000. Marshall Wace LLP increased its stake in shares of Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares during the last quarter. Finally, Wellington Management Group LLP bought a new position in Novo Nordisk A/S during the third quarter valued at $42,017,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on NVO. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $150.40.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $106.96 on Friday. The business’s fifty day moving average is $110.59 and its 200 day moving average is $126.27. The firm has a market cap of $479.99 billion, a price-to-earnings ratio of 34.61, a PEG ratio of 1.43 and a beta of 0.40. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52-week low of $96.53 and a 52-week high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.